Quick Dispatch:
Your retatrutide triple agonist weight loss The power of three: Retatrutide's role in modern obesity and diabetes therapy orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your retatrutide triple agonist weight loss The power of three: Retatrutide's role in modern obesity and diabetes therapy ships.
Need Help?
Questions about retatrutide triple agonist weight loss The power of three: Retatrutide's role in modern obesity and diabetes therapy, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for retatrutide triple agonist weight loss The power of three: Retatrutide's role in modern obesity and diabetes therapy in your area.
Today we shared new results on retatrutide, an investigational, first-of-its-kind treatment we're studying in adults with obesity or overweight with at least one weight-related comorbidity. Read more about the Phase 3 findings:
27.75
First Retatrutide phase 3 data, a Triumph of Science!
29.46
🚨 Retatrutide TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% Weight loss at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35
26.13
What Does Retatrutide Do? How the Triple-Agonist Works
20.88
Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial
27.89
Retatrutide Obesity: Triple-Agonist Weight Loss
21.70
retatrutide is a novel triple agonist peptide at the glucagon receptor, GIP receptor, and GLP-1 receptor. 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide. @LillyPad #medtwitter #endotwitter
28.48
